Xylem Inc.
108.74USD
-0.5200 (-0.48%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on XYL.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.45▼ | $1.46 | 0 | 1 |
| Next quarter | $1.64▲ | $1.63 | 0 | 3 |
| Current year | $5.65▲ | $5.54 | 1 | 2 |
| Next year | $6.22▲ | $6.1 | 1 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.34 | $1.46 | +0.12 (+9.2%) |
| 2026-03-31 | $1.08 | $1.12 | +0.04 (+3.3%) |
| 2025-12-31 | $1.41 | $1.42 | +0.01 (+0.8%) |
| 2025-09-30 | $1.23 | $1.37 | +0.14 (+11.1%) |
266 ratings from 42 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Neutral | $137 $118 | Oct 19, 2026 |
| Mizuho | Maintained | Neutral | $130 $110 | Oct 15, 2026 |
| Oppenheimer | Reiterated | Outperform | $158 $150 | Oct 14, 2026 |
| RBC Capital | Maintained | Outperform | $164 $135 | Oct 14, 2026 |
| Barclays | Maintained | Overweight | $159 $139 | Oct 13, 2026 |
| Citigroup | Maintained | Buy | $172 $148 | Oct 12, 2026 |
| UBS | Maintained | Neutral | $138 $112 | Oct 5, 2026 |
| Jefferies | Maintained | Buy | $145 $150 | Aug 24, 2026 |
| UBS | Maintained | Neutral | $135 $138 | Aug 13, 2026 |
| UBS | Maintained | Neutral | $129 $135 | Jul 30, 2026 |
| Stifel | Maintained | Buy | $157 $160 | Jul 29, 2026 |
| Mizuho | Maintained | Neutral | $124 $130 | Jul 29, 2026 |
| RBC Capital | Maintained | Outperform | $159 $164 | Jul 29, 2026 |
| Barclays | Maintained | Overweight | $154 $159 | Jul 29, 2026 |
| Baird | Maintained | Outperform | $163 $165 | Jul 29, 2026 |
| Stifel | Maintained | Buy | $159 $157 | Jul 20, 2026 |
| RBC Capital | Maintained | Outperform | $157 $159 | Jul 16, 2026 |
| Jefferies | Upgraded from Hold | Buy | $130 $140 | Jun 25, 2026 |
| UBS | Maintained | Neutral | $132 $133 | Apr 29, 2026 |
| Citigroup | Maintained | Buy | $174 $168 | Apr 29, 2026 |
| Oppenheimer | Maintained | Outperform | $160 $158 | Apr 29, 2026 |
| Barclays | Maintained | Overweight | $156 $154 | Apr 29, 2026 |
| Stifel | Maintained | Buy | $163 $159 | Apr 29, 2026 |
| UBS | Downgraded from Buy | Neutral | $152 $132 | Apr 21, 2026 |
| JP Morgan | Maintained | Overweight | $170 $160 | Apr 16, 2026 |
71 filings from 24 insiders · 13 buy / 1 sell over 6m
Officers and directors of XYL, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Emmerich MeredithOfficer, EVP & President, MCS | Tax | 837 | $106.35 | $89k | Oct 21, 2026 |
| McShane Geri-MichelleOfficer, SVP, CAO | Grant | 4.3k | — | — | Oct 1, 2026 |
| McShane Geri-MichelleOfficer, SVP, CAO | Grant | 4.2k | — | — | Oct 1, 2026 |
| van der Berg Andrea MicheleOfficer, EVP & Chief Financial Officer | GrantStock Options (Right to Buy) | 6.0k | $106.89 | $645k | Sep 1, 2026 |
| van der Berg Andrea MicheleOfficer, EVP & Chief Financial Officer | Grant | 1.7k | — | — | Sep 1, 2026 |
| Johnston Joseph PatrickOfficer, EVP & President, AW | GrantStock Options (Right to Buy) | 2.3k | $106.89 | $246k | Sep 1, 2026 |
| Johnston Joseph PatrickOfficer, EVP & President, AW | Grant | 645 | — | — | Sep 1, 2026 |
| KOCH DALE CHRISTIANDirector | Grant | 1.2k | $120.27 | $150k | Aug 13, 2026 |
| FRIEL ROBERT FDirector | Grant | 2.5k | $116.88 | $290k | May 14, 2026 |
| GLATCH LISADirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| MORELLI MARK DDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| PERIBERE JEROME ADirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| TRETIKOV LILADirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| YADAV UDAYDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| HARKER VICTORIA DDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| ELLIS EARL RAYDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| MCSHANE GERI-MICHELLEOfficer | Sell | 4.3k | $117.46 | $501k | May 7, 2026 |
| MCSHANE GERI-MICHELLEOfficer | Exercise | 3.1k | $86.76 | $273k | May 7, 2026 |
| PERIBERE JEROME ADirector | Buyindirect | 1.2k | $116.61 | $141k | May 4, 2026 |
| TOUSSAINT CLAUDIA SOfficer | Grant | 9.4k | — | $954k | Mar 2, 2026 |
No analyst notes on XYL yet.
Analyst Ratings
16 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 10 | 7 | 0 | 0 | Buy2.14 |
| 1 mo ago | 4 | 10 | 7 | 0 | 0 | Buy2.14 |
| 2 mo ago | 4 | 10 | 7 | 0 | 0 | Buy2.14 |
| 3 mo ago | 3 | 11 | 9 | 0 | 0 | Buy2.26 |
Members whose judged calls on XYL have played out most reliably.
No settled calls on XYL yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice